The Antiplatelet Efficacy Of Low-dose Ticagrelor In Chinese SCAD Patients: An Open-label Randomized Controlled Trial

Background:Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the standard in coronary artery disease(CAD)patients.Ticagrelor has a greater antiplatelet efficacy than clopidogrel but may be accompanied by an increased risk of bleeding.Therefore,we performed this study to observe the efficacy of half standard dose ticagrelor in Chinese patients with stable CAD.Methods: In a randomized,single-blind,crossover trial,60 patients with stable CAD were randomized to standard dose ticagrelor(90mg BID for 7days)?half standard dose ticagrelor(45 mg BID for 7 days)?one-quarter dose ticagrelor(22.5 mg BID for 7 days)and standard-dose clopidogrel(75 mg QD for 7 days).Thrombus map and PL-12 Platelet function analysis were used to measure platelet function.Venous blood samples were taken at pre-treatment,and the seventh day after taking drugs.Results:1.Thr results of ADP inhibition?MAR?MAADP were similar before treatment.2.ADP inhibition were similar between in 45 mg ticagrelor and 90 mg ticagrelor,the results were higher than other two groups.MAR and MAADP were similar between 45 mg ticagrelor and 90 mg ticagrelor,which were lower than other two groups.3.There were no side effects in low dose ticagrelor groups.Conclusions: In chinese stable CAD patients,45 mg maybe an optimal option with higher platelet inhibition.Due to the results lack of long-term setback,the more trails were needed.